| A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia. DJ DeAngelo, S Dahlberg, LB Silverman, S Couban, PC Amrein, ... Blood, The Journal of the American Society of Hematology 110 (11), 587-587, 2007 | 80 | 2007 |
| A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG–ACRIN Cancer Research Group (E2511) TK Owonikoko, SE Dahlberg, SA Khan, DE Gerber, J Dowell, RA Moss, ... Lung Cancer 89 (1), 66-70, 2015 | 65 | 2015 |
| A phase 1 study of veliparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (SCLC … TK Owonikoko, SE Dahlberg, SA Khan, DE Gerber, J Dowell, RA Moss, ... Journal of Clinical Oncology 32 (15_suppl), 7523-7523, 2014 | 5 | 2014 |
| A Phase 1 trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast … JF Liu, SM Tolaney, M Birrer, GF Fleming, MK Buss, SE Dahlberg, H Lee, ... European journal of cancer (Oxford, England: 1990) 49 (14), 2972, 2013 | 6 | 2013 |
| A phase 1 trial of the poly (ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or … JF Liu, SM Tolaney, M Birrer, GF Fleming, MK Buss, SE Dahlberg, H Lee, ... European journal of cancer 49 (14), 2972-2978, 2013 | 208 | 2013 |
| A Phase 1/2 Study of alectinib in RET-rearranged non-small cell lung cancer or RET-mutated thyroid cancer Coordinating Center: Dana-Farber/Harvard Cancer Center S Dahlberg, S Clifford, E Kelley, B Marion | | |
| A phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide in patients with stage III non-small cell carcinoma of the lung (NSCLC … JH Schiller, SE Dahlberg, M Mehta, DH Johnson Journal of Clinical Oncology 27 (15_suppl), 7503-7503, 2009 | 13 | 2009 |
| A pilot trial of rapamycin with glucocorticoids in children and adults with relapsed ALL KD Schlis, M Stubbs, DJ DeAngelo, D Neuberg, SE Dahlberg, SE Sallan, ... Blood 116 (21), 3244, 2010 | 5 | 2010 |
| A proportional hazards cure model for the analysis of time to event with frequently unidentifiable causes SE Dahlberg, M Wang Biometrics 63 (4), 1237-1244, 2007 | 4 | 2007 |
| A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II … M Yanagita, AJ Redig, CP Paweletz, SE Dahlberg, A O'Connell, N Feeney, ... Clinical Cancer Research 22 (24), 6010-6020, 2016 | 119 | 2016 |
| A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512 JW Neal, SE Dahlberg, HA Wakelee, SC Aisner, M Bowden, DP Carbone, ... JOURNAL OF THORACIC ONCOLOGY 10 (9), S373-S373, 2015 | 2 | 2015 |
| A randomized phase III study of maintenance therapy with bevacizumab (B), pemetrexed (Pm), or a combination of bevacizumab and pemetrexed (BPm) following carboplatin … SE Dahlberg, SS Ramalingam, CP Belani, JH Schiller Journal of Clinical Oncology 29 (15_suppl), TPS218-TPS218, 2011 | 19 | 2011 |
| A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after … KJ Pandya, S Dahlberg, M Hidalgo, RB Cohen, MW Lee, JH Schiller, ... Journal of Thoracic Oncology 2 (11), 1036-1041, 2007 | 170 | 2007 |
| ABSENCE OF BIALLELIC TCR gamma DELETIONS (ABGD) PREDICTS INDUCTION FAILURE IN PEDIATRIC T-ALL A Gutierrez, S Dahlberg, D Neuberg, J Zhang, R Grebliunaite, T Sanda, ... PEDIATRIC BLOOD & CANCER 54 (6), 812-812, 2010 | | 2010 |
| ABSENCE OF BIALLELIC TCR gamma LOCUS DELETIONS PREDICTS EARLY TREATMENT FAILURE IN PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA A Gutierrez, S Dahlberg, D Neuberg, J Zhang, R Grebliunaite, T Sanda, ... PEDIATRIC BLOOD & CANCER 55 (5), 834-834, 2010 | | 2010 |
| Absence of biallelic TCRγ deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia A Gutierrez, SE Dahlberg, DS Neuberg, J Zhang, R Grebliunaite, T Sanda, ... Journal of clinical oncology 28 (24), 3816, 2010 | 117 | 2010 |
| Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane EV Barry, LM Vrooman, SE Dahlberg, DS Neuberg, BL Asselin, UH Athale, ... Journal of Clinical Oncology 26 (7), 1106-1111, 2008 | 140 | 2008 |
| Absence of T-Cell Receptor Gene Rearrangements Predicts Induction Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. A Gutierrez, R Grebliunaite, SE Dahlberg, D Neuberg, J Zhang, T Sanda, ... Blood 114 (22), 910, 2009 | 1 | 2009 |
| abstract Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications B Ricciuti, SE Dahlberg, A Adeni, LM Sholl, M Nishino | | 2019 |
| ACADEMIC APPOINTMENTS SE Dahlberg | | 2012 |
Geoffrey R. Oxnard, MDLoxo Oncology @ Lilly在 loxooncology.com 的电子邮件经过验证
